• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Epigenetics Technology Market (Epigenomics, DNA Methylation, Histone Modifications, RNA Interference, Cancer Therapeutics, Personalized Medicine) (2012 - 2017) - Product Image

Epigenetics Technology Market (Epigenomics, DNA Methylation, Histone Modifications, RNA Interference, Cancer Therapeutics, Personalized Medicine) (2012 - 2017)

  • Published: January 2013
  • Region: Global
  • 156 Pages
  • Markets and Markets

FEATURED COMPANIES

  • 4SC (GERMANY)
  • CELGENE (U.S.)
  • CELLCENTRIC (U.K.)
  • CH3 BIOSYSTEMS (U.S.)
  • COVARIS INC. (U.S.)
  • EISAI CO. LTD. (JAPAN)
  • MORE

Over the last decade, genomics and proteomics have been used as key tools to discover potential drug targets and to better understand the complexities of biology. To balance research in these areas, epigenetics offers a potential opportunity in understanding the basis of various diseases in a different approach. Thus, epigenetics is study of heritable changes in genome function and gene expression had opened the new gate of biology to understand the basis of diseases and presents incredible opportunities for disease diagnosis and drug discovery.

Report covers the market by therapeutics sector in oncology conditions, non-oncology indications and personalized medicine. The report also covers the market by research and diagnostics sector in gene regulation studies, biomarker detection and drug discovery. In addition, it also includes the factors driving and restraining the market and covers the market scenario in the U.S., Europe, Asia and the Rest of the World (ROW). This report will provide the company profiles of key companies along with the competitive analysis.

The Global Epigenetics market is showing a double digit growth (CAGR 25%) due to supportive factors such as, READ MORE >

1. Introduction
1.1 Key Take-Aways
1.2 Report Scope
1.3 Research Methodology
1.4 Key Data Points From Primary And Secondary Sources

2. Executive Summary

3. Epigenetics – Technology Landscape Analysis
3.1 Technology Overview
3.2 Technology Evolution – Milestones In Epigenetics
3.3 Epigenetic Mechanisms
3.3.1 Dna Methylation
3.3.2 Histone Modifications
3.3.3 Rna Interference
3.4 Technology Value Chain Analysis
3.5 Applications
3.5.1 Therapeutics
3.5.1.1 Oncology Conditions
3.5.1.2 Non-Oncology Indications
3.5.1.3 Personalized Medicine
3.5.2 Research And Diagnostics
3.5.2.1 Gene Regulation Studies
3.5.2.2 Biomarker Detection
3.5.2.3 Drug Discovery
3.6 Epigenetics – Technology Innovations And Products With Applications
3.7 Current Scenario In Epigenetics
4. Epigenetics – Market Landscape Analysis
4.1 Epigenetics Market Size – Potential Addressable Market
4.2 Global Epigenetics Market Segmentation
4.3 Global Market Revenue Forecast (2012-2017)
4.3.1 By Geography
4.3.2 By Applications
4.3.3 By Epigenetic Mechanisms
4.4 Market Share Of Companies
4.5 Market Dynamics
4.5.1 Drivers
4.5.2 Restraints
4.5.3 Challenges

5. Technology Investment Potential
5.1 Investor Network
5.1.1 Some Funds And Investments By Public Funding Bodies
5.1.2 Some Funds And Investments By Non-Government Organizations (Ngos)
5.1.3 Some Investments By Corporate, Private And Equity Investors
5.1.4 Insights On Current And Future Tech-Investment Trends
5.1.5 Funding Patterns And Investor Inclination

5.2 Investment Opportunities
5.2.1 Epigenetic Technologies And Products Available For
Licensing & Acquisition For Stakeholders
5.2.2 Analysis Of Potential Application Areas For Technology
Investment – Based On Opportunity Strategy Evaluation (Ose) Analysis

6. Epigenetics – Technology Adoption Potential And Development By Geography
6.1 Introduction
6.2 North America
6.3 Europe
6.4 Asia
6.5 Row
6.6 Demand Side Analysis

7. Epigenetics Competitive Landscape
7.1 Key Mergers And Acquisitions
7.2 Partnerships And Collaborations
7.3 Therapeutic Drugs In Pipeline
7.4 Worldwide Consortiums And Networks In Epigenetics

8. Intellectual Property And Research Strength Analysis
8.1 Ip Strength Analysis Of Epigenetics Between 2008-2012
8.2 Analysis Of Research Strength From Ncbi Pubmed Publications

9. Analyst Insights And Recommendations
9.1 Analyst Insights
9.2 Analyst Recommendations
9.3 Open Opportunity Invitations In The Field For Business Development

10. Company Profiles

10.1 4Sc (Germany)
10.2 Celgene (U.S.)
10.3 Cellcentric (U.K.)
10.4 Ch3 Biosystems (U.S.)
10.5 Covaris Inc. (U.S.)
10.6 Eisai Co. Ltd. (Japan)
10.7 Epiontis (Germany)
10.8 Epitherapeutics (Denmark)
10.9 Epizyme (U.S.)
10.10 Karus Therapeutics (U.K.)
10.11 Merck Millipore (U.S.)
10.12 Ribomed Biotechnologies (U.S.)

11. Appendix
12. Glossary

List of Tables

Table 1 Global Epigenetics Market Revenue, By Geography, 2012–2017 ($Million)
Table 2 Global Epigenetics Market Revenue, By Application Segments, 2012–2017 ($Million)
Table 3 Global Epigenetics Market Revenue, By Therapeutic Applications, 2012–2017 ($Million)
Table 4 Global Epigenetics Market Revenue, By Research & Diagnostics Applications, 2012–2017 ($Million)
Table 5 Global Epigenetics Market Revenue, By Epigenetic Mechanisms, 2012–2017 ($Million)
Table 6 Market Share Of Companies Based On Currently Available Four Drugs
Table 7 Some Funds And Investments By Public Funding Bodies
Table 8 Epidemiology And Genomics Research Program (Egrp) Funding Details For Epigenetics
Table 9 Nih Funding Details For Epigenetics
Table 10 Some Funds And Investments By Non-Government Organizations (Ngos)
Table 11 Some Investments By Corporate, Private And Equity Investors
Table 12 Worldwide Incidence & Mortality Of Selected Cancers (Cases/Year)
Table 13 Mergers And Acquisitions
Table 14 Partnerships And Collaborations
Table 15 Therapeutic Drugs In Pipeline
Table 16 Key Patents
Table 17 Different Types Of Products For Epigenetic Mechanisms – Dna Methylation
Table 18 Different Types Of Products For Epigenetic Mechanisms – Histone Modifications
Table 19 Different Types Of Products For Epigenetic Mechanisms – Rna Interference

List Of Figures

Fig 1 Global Market Of Epigenetics 2012–2017 ($Million)
Fig 2 Global Epigenetics Market Revenue, By Geography, 2012–2017 ($Million)
Fig 3 Global Epigenetics Market Share – By Geography
Fig 4 Global Epigenetics Market Revenue, By Application Segments,2012-2017 ($Million)
Fig 5 Global Epigenetics Market Revenue, By Therapeutic Applications, 2012–2017 ($Million)
Fig 6 Global Epigenetics Market Revenue, By Research & Diagnostics Applications, 2012–2017 ($Million)
Fig 7 Global Epigenetics Market Share – By Applications
Fig 8 Global Epigenetics Market Revenue, By Epigenetic Mechanisms, 2012–2017 ($Million)
Fig 9 Market Share Of Companies Based On Currently Available Four Drugs
Fig 10 Epidemiology And Genomics Research Program (Egrp) Funding Details For Epigenetics
Fig 11 Nih Funding Details For Epigenetics
Fig 12 Epigenetics, Year-Wise Funding Patterns & Investment Forecast (2012–2017)
Fig 13 Current Funding Pattern By Investors For Epigenetics
Fig 14 Patents Published Between 2008-2012
Fig 15 Pubmed Publications Between 2008-2012
Fig 16 Pubmed Publications On Epigenetic Enzymes 2008-2012

- 4SC (GERMANY)
- CELGENE (U.S.)
- CELLCENTRIC (U.K.)
- CH3 BIOSYSTEMS (U.S.)
- COVARIS INC. (U.S.)
- EISAI CO. LTD. (JAPAN)
- EPIONTIS (GERMANY)
- EPITHERAPEUTICS (DENMARK)
- EPIZYME (U.S.)
- KARUS THERAPEUTICS (U.K.)
- MERCK MILLIPORE (U.S.)
- RIBOMED BIOTECHNOLOGIES (U.S.)

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos